Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod

Journal of Immunology

Volumn 174, Issue 5, 2005, Pages 2476-2480

  Rechtsteiner, Gerd ^a   Warger, Tobias ^a   Osterloh, Philipp ^a,b   Schild, Hansjörg ^a,b   Radsak, Markus P ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; IMIQUIMOD; LYMPHOCYTE ANTIGEN; PEPTIDE; SERYLGLYCYLPROLYLSERYLASPARAGINYLTHREONYLPROLYLPROLYLGLUTAMYLISOLEUCINE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPROPHYLAXIS; INTERFERON PRODUCTION; MOUSE; NONHUMAN; OINTMENT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VIRUS INFECTION; WILD TYPE;

EID: 14044265101     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.5.2476     Document Type: Article

References (27)

1. Kaech, S. M., E. J. Wherry, and R. Ahmed. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251.
2. Steinman, R. M., and M. C. Nussenzweig. 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99:351.
3. Jonuleit, H., A. Giesecke-Tuettenberg, T. Tuting, B. Thurner-Schuler, T. B. Stuge, L. Paragnik, A. Kandemir, P. P. Lee, G. Schuler, J. Knop, and A. H. Enk. 2001. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93:243.
4. Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475.
5. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685.
6. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:257.
7. Vabulas, R. M., S. Braedel, N. Hilf, H. Singh-Jasuja, S. Herter, P. Ahmad-Nejad, C. J. Kirschning, C. Da Costa, H. G. Rammensee, H. Wagner, and H. Schild. 2002. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J. Biol. Chem. 277:20847.
8. Braedel, S., M. Radsak, H. Einsele, J. P. Latge, A. Michan, J. Loeffler, Z. Haddad, U. Grigoleit, H. Schild, and H. Hebart. 2004. Aspergillus famigatus antigens activate innate immune cells via Toll-like receptors 2 and 4. Br. J. Haematol. 125:392.
9. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987.
10. Glenn, G. M., D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:1403.
11. Romani, N., S. Koide, M. Crowley, M. Witmer-Pack, A. M. Livingstone, C. G. Fathman, K. Inaba, and R. M. Steinman. 1989. Presentation of exogenous protein antigens by dendritic cells to T cell clones: intact protein is presented best by immature, epidermal Langerhans cells. J. Exp. Med. 169:1169.
12. World Heath Organization Expanded Programme on Immunization. 1996. Reducing the risk of unsafe injections in immunization programmes: the role of injection equipment. World Health Organization, Geneva, Switzerland.
13. Thomsen, L. L., P. Topley, M. G. Daly, S. J. Brett, and J. P. Tite. 2004. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22:1799.
14. Klimuk, S. K., H. M. Najar, S. C. Semple, S. Aslanian, and J. P. Dutz. 2004. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL. J. Invest Dermatol. 122:1042.
15. Belyakov, I. M., S. A. Hammond, J. D. Ahlers, G. M. Glenn, and J. A. Berzofsky. 2004. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113:998.
16. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196.
17. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303:1526.
18. Navi, D., and A. Huntley. 2004. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol. Online J. 10:4.
19. Fleming, C. J., A. M. Bryden, A. Evans, R. S. Dawe, and S. H. Ibbotson. 2004. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br. J. Dermatol. 151:485.
20. Di, L., V. C. Ricci, and G. Albertini. 2004. Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream. J. Eur. Acad. Dermatol. Venereol. 18:626.
21. Beutner, K. R., J. K. Geisse, D. Helman, T. L. Fox, A. Ginkel, and M. L. Owens. 1999. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J. Am. Acad. Dermatol. 41:1002.
22. Stanley, M. A. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27:571.
23. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.
24. Hofmann, M., M. Radsak, G. Rechtsteiner, K. Wiemann, M. Gunder, U. Bien-Grater, R. Offringa, R. E. Toes, H. G. Rammensee, and H. Schild. 2004. T cell avidity determines the level of CTL activation. Eur. J. Immunol. 34:1798.
25. Palamara, F., S. Meindl, M. Holcmann, P. Luhrs, G. Stingl, and M. Sibilia. 2004. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. 173:3051.
26. Nair, S., C. McLaughlin, A. Weizer, Z. Su, D. Boczkowski, J. Dannull, J. Vieweg, and E. Gilboa. 2003. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171:6275.
27. Melief, C. J., S. H. van der Burg, R. E. Toes, F. Ossendorp, and R. Offringa. 2002. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188:177.